Fisher Asset Management LLC Acquires New Shares in Dyne Therapeutics, Inc. $DYN

Fisher Asset Management LLC acquired a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the 4th quarter, Holdings Channel.com reports. The fund acquired 250,065 shares of the company’s stock, valued at approximately $4,891,000.

Other institutional investors also recently modified their holdings of the company. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics during the third quarter valued at $30,000. Strs Ohio bought a new position in Dyne Therapeutics in the fourth quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after acquiring an additional 1,109 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the period. Finally, Prudential Financial Inc. bought a new position in Dyne Therapeutics in the second quarter valued at about $111,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 287,956 shares of Dyne Therapeutics stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total transaction of $5,666,974.08. Following the transaction, the director directly owned 11,663 shares of the company’s stock, valued at $229,527.84. The trade was a 96.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders bought 7,500 shares of company stock worth $124,400 and sold 1,559,462 shares worth $29,814,746. 14.14% of the stock is currently owned by insiders.

Dyne Therapeutics Stock Up 2.2%

DYN stock opened at $18.56 on Friday. The business’s 50-day moving average is $18.27 and its two-hundred day moving average is $18.31. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company has a market cap of $3.07 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the previous year, the firm earned ($1.05) EPS. As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on DYN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Sanford C. Bernstein increased their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Finally, HC Wainwright lowered their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.00.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.